rethinkTHC Search
Menu
Study breakdown

Cannabinoids Show Promise Against Cervical Cancer, Especially With Nanotechnology Delivery

ReviewPreliminary evidence
The takeaway

A review of preclinical evidence finds THC and CBD have anticancer effects in cervical cancer through apoptosis, proliferation inhibition, and immune modulation, with nanotechnology-based delivery systems showing enhanced efficacy.

Cancer researchers, oncologists, and anyone following cannabinoid anticancer research.

Multiple anticancer mechanisms identified in preclinical cervical cancer studies

What the researchers found

THC and CBD demonstrate anticancer effects in cervical cancer cells by inducing apoptosis, inhibiting proliferation, suppressing metastasis, promoting oxidative stress, and modulating immune responses. Combining cannabinoids with chemotherapy, radiotherapy, or immunotherapy enhanced efficacy and reduced drug resistance. Nanoparticle delivery systems improved targeting, solubility, and reduced systemic toxicity.

Why it matters

Cervical cancer remains a major health challenge, particularly in sub-Saharan Africa. Cannabinoids represent a new class of potential therapeutic agents, and nanotechnology may solve key delivery challenges that have limited their clinical application.

The numbers in context

Review covers multiple mechanisms: apoptosis induction, proliferation inhibition, metastasis suppression, oxidative stress promotion, immune modulation. Combination approaches with chemo, radio, and immunotherapy reviewed.

How the study worked

Critical synthesis of preclinical studies examining cannabinoid anticancer properties in cervical cancer, including combination therapy approaches and nanotechnology-based delivery platforms.

What this study cannot tell us

All evidence is preclinical. No human clinical trials for cannabinoids in cervical cancer exist. Optimal formulations, doses, and delivery routes remain to be determined. Regulatory challenges for cannabinoid-based medicines persist.

How to read the evidence

Review of preclinical evidence only. No human clinical data for this specific application.

When this study was published

Published in 2025.

The bigger picture

The convergence of cannabinoid research with nanotechnology and combination therapy represents a new frontier in cancer treatment. If these preclinical findings translate clinically, cannabinoid-based nanoformulations could complement existing cervical cancer treatments.

Questions still open

  • When will the first clinical trials of cannabinoid nanoformulations for cervical cancer begin? Could these approaches also work for HPV-related cancers beyond the cervix?

Common questions

Can cannabinoids treat cervical cancer?
Preclinical studies show promise, but no human clinical trials exist yet. The research is in early stages and primarily based on cell and animal models.
Why nanotechnology?
Cannabinoids are poorly soluble and difficult to deliver to tumors at therapeutic concentrations. Nanoparticles can improve targeting, increase drug concentration at the tumor site, and reduce side effects.

Read the original research

Advancing cervical cancer treatment: integrating cannabinoids, combination therapies and nanotechnology.

Journal of cancer research and clinical oncology, 151(11), 294

Citation

Mathibela, S P; Ncube, K N; Lebelo, M T; Steenkamp, V. (2025). Advancing cervical cancer treatment: integrating cannabinoids, combination therapies and nanotechnology.. Journal of cancer research and clinical oncology, 151(11), 294. https://doi.org/10.1007/s00432-025-06323-6

Explore the wider topic